Y
Yukinori Kurokawa
Researcher at Osaka University
Publications - 438
Citations - 9930
Yukinori Kurokawa is an academic researcher from Osaka University. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 45, co-authored 354 publications receiving 7601 citations. Previous affiliations of Yukinori Kurokawa include Nara Institute of Science and Technology.
Papers
More filters
Journal ArticleDOI
D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer.
M. Sasako,Takeshi Sano,Seiichiro Yamamoto,Yukinori Kurokawa,Atsushi Nashimoto,Akira Kurita,Masahiro Hiratsuka,Toshimasa Tsujinaka,Taira Kinoshita,Kuniyoshi Arai,Yoshitaka Yamamura,Kunio Okajima +11 more
TL;DR: Treatment with D2 lymphadenectomy plus PAND does not improve the survival rate in curable gastric cancer, and no significant differences in recurrence-free survival are found.
Journal ArticleDOI
Extended Clavien-Dindo classification of surgical complications: Japan Clinical Oncology Group postoperative complications criteria
Hiroshi Katayama,Yukinori Kurokawa,Kenichi Nakamura,Hiroyuki Ito,Yukihide Kanemitsu,Norikazu Masuda,Yasuhiro Tsubosa,Toyomi Satoh,Akira Yokomizo,Haruhiko Fukuda,Mitsuru Sasako +10 more
TL;DR: The JCOG postoperative complications criteria (JCOG PC criteria) aim to standardize the terms used to define adverse events (AEs) and provide detailed grading guidelines based on the Clavien-Dindo classification.
Journal ArticleDOI
Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial
Kazumasa Fujitani,Han-Kwang Yang,Junki Mizusawa,Young-Woo Kim,Masanori Terashima,Sang-Uk Han,Yoshiaki Iwasaki,Woo Jin Hyung,Akinori Takagane,Do Joong Park,Takaki Yoshikawa,Seokyung Hahn,Kenichi Nakamura,Cho Hyun Park,Yukinori Kurokawa,Yung-Jue Bang,Byung Joo Park,Mitsuru Sasako,Toshimasa Tsujinaka +18 more
TL;DR: Since gast rectomy followed by chemotherapy did not show any survival benefit compared with chemotherapy alone in advanced gastric cancer with a single non-curable factor, gastrectomy cannot be justified for treatment of patients with these tumours.
Journal ArticleDOI
Overexpression of miR-200c Induces Chemoresistance in Esophageal Cancers Mediated Through Activation of the Akt Signaling Pathway
Rie Hamano,Hiroshi Miyata,Makoto Yamasaki,Yukinori Kurokawa,Johji Hara,Jeong Ho Moon,Kiyokazu Nakajima,Shuji Takiguchi,Yoshiyuki Fujiwara,Masaki Mori,Yuichiro Doki +10 more
TL;DR: Results of this study emphasized the involvement of miR-200c in resistance to chemotherapy among esophageal cancers and that this effect was mediated through the Akt pathway.
Journal ArticleDOI
A non-randomized confirmatory trial of an expanded indication for endoscopic submucosal dissection for intestinal-type gastric cancer (cT1a): the Japan Clinical Oncology Group study (JCOG0607).
Noriaki Hasuike,Hiroyuki Ono,Narikazu Boku,Junki Mizusawa,Kohei Takizawa,Haruhiko Fukuda,Ichiro Oda,Hisashi Doyama,Kazuhiro Kaneko,Shinichiro Hori,Hiroyasu Iishi,Yukinori Kurokawa,Manabu Muto +12 more
TL;DR: ESD for early gastric cancers that met the expanded criteria for intestinal-type gastric cancer (cT1a) was acceptable and should be the standard treatment instead of gastrectomy.